AIFM2 and hepatocellular carcinoma: In preclinical studies, the FSP1 inhibitor iFSP1 has been demonstrated to promote ferroptosis in hepatocellular carcinoma and enhance the anti-tumor immune response by stimulating the infiltration of dendritic cells, macrophages, and T cells [73].